Lupus & antiphospholipid syndrome
Clinical and biologic predictors of thrombosis in persistently antiphospholipid antibody-positive patients: Prospective analysis of the International APS ACTION Clinical Database and Repository (‘Registry’)
Authors' conclusion
In this prospective analysis, history of thrombosis and hematologic disease each conferred an approximately twofold increased risk of new thrombosis in persistently aPL-positive patients.
Study context
- Population
- Persistently aPL-positive patients (Revised Sapporo Classification Criteria) in the APS ACTION Registry with at least 1 year of follow-up
- Participants
- 1,067 patients4,727 person-years
- Exposure
- Clinical and biologic predictors of new thrombosis in persistently aPL-positive patients
- New thrombosisn = 93
- No new thrombosisn = 974reference
- Outcome
- New thrombosis (independent predictors)
Methodological detailsinternational registry, Cox proportional hazards models
- International registry
- Cox proportional hazards models
Main finding
As reported in the abstract
Independent predictors of new thrombosis (adjusted) · mean follow-up of 4.43 years
Hazard ratio (95% CI)P value
History of thrombosis
2.34(1.14–4.81)
P = 0.02Hematologic diseaseautoimmune haemolytic anaemia and/or thrombocytopenia
1.95(1.19–3.18)
P = 0.01Observational data: associations, not effects.
Further findings
Unadjusted: factors more frequent with new thrombosis
- History of thrombosis, hematologic disease, microvascular disease, obesity, renal disease, sedentary lifestyle, baseline anticoagulant use and family history of early CVD occurred more frequently among patients with new thrombosis
- P < 0.05
Original publication
Clinical and biologic predictors of thrombosis in persistently antiphospholipid antibody-positive patients: Prospective analysis of the International APS ACTION Clinical Database and Repository (‘Registry’). Ann Rheum Dis. Published 19 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →